HR+/HER2- non-metastatic disease adjuvant management in 2022.
Marc SPIELMANN, Joseph GLIGOROV
New User? Click here to register
Text generated by AI based on an exclusive interview, revised and reviewed by
Marc SPIELMANN, Joseph GLIGOROV
Frédérique PENAULT LLORCA Pathologist, Clermont Ferrand, France
Copyright © 2026 - BCU